hrp0089rfc14.2 | Multisystem Endocrine Disorders | ESPE2018

British Society for Paediatric Endocrinology and Diabetes Peer Review of Specialised Paediatric Endocrinology Services in the UK - Evaluation of the Outcomes

Schulga Joihn , Mitchell Heather , Musson Pauline , Shaw Nick , Patel Leena

Introduction: The BSPED Peer review programme was initiated in 2011 to provide a regular cycle of independent impartial professional assessment, against quality standards for Specialised Paediatric Endocrine Services (SPES) in the UK.1 We present here an evaluation of the outcomes from the first review cycle completed in 2017.Methods: We examined pre-review self-assessments (4–6 weeks before a site visit by the Peer Review team) and post-...

hrp0089p2-p217 | GH & IGFs P2 | ESPE2018

The BSPED National GH Audit: Trends in Prescribing from 2013–2016

Patel Leena , Shepherd Sheila , Shaw Nick , Saraff Vrinda

Introduction: Prescribing of recombinant human GH for growth failure in UK children is based on guidance from the National Institute of Clinical Excellence. In 2013, the BSPED initiated this national audit of children/adolescents newly-prescribed GH to monitor trends in NHS prescribing practice. Here we have examined these trends from 2013 to 2016.Patient population: All patients aged ≤16.0 years newly starting GH therapy in the UK.<p class="ab...

hrp0089p2-p294 | Multisystem Endocrine Disorders P2 | ESPE2018

British Society for Paediatric Endocrinology and Diabetes Peer Review of Specialised Paediatric Endocrinology Services in the UK - Evaluation of the Process

Schulga John , Mitchell Heather , Musson Pauline , Shaw Nick , Patel Leena

Introduction: The BSPED Peer review programme was developed to provide a regular cycle of independent impartial professional assessment, against agreed quality standards for Specialised Paediatric Endocrine Services (SPES) in the UK.1 The aim is to continuously promote best quality of care for children and young people with endocrine disorders requiring National Health Service treatment at a SPES. We present here an evaluation of the process during this first revie...

hrp0089p1-p250 | Thyroid P1 | ESPE2018

Thyroid Scintigraphy in the Diagnosis of Congenital Hypothyroidism

Woth Chris , Banerjee Indi , Hird Beverley , Patel Leena , Tetlow Lesley

Background: Identification of Congenital Hypothyroidism (CH) is an essential part of Newborn Bloodspot Screening (NBS) in the UK. NBS for CH relies on Blood Spot (BS) Thyroid Stimulating Hormone (TSH) measurement in newborns on day 5 of life. Diagnostic confirmation of a screen positive result requires measurement of plasma/serum free thyroxine (fT4) and TSH but technetium thyroid scanning is not mandatory. Technetium-99m scintigraphy can be used to define siz...

hrp0095p1-209 | Adrenals and HPA Axis | ESPE2022

Systematic review of cortisol levels during acute illnesses in children and young people not known to have glucocorticoid deficiency

Banerjee Indraneel , Patel Leena , Fullwood Catherine , Hird Beverly , Chawla Meghna , Tetlow Lesley , Rezai Mohammad

Importance: Current practice of doubling or trebling the basal glucocorticoid (GC) replacement dose during acute illnesses in children and young people (CYP) with GC deficiency is extrapolated from research in adults and not based on robust evidence. Endogenous cortisol levels during acute illnesses in CYP without GC deficiency can provide insight for optimal GC stress dosing for CYP with GC deficiency.Objective: To summ...

hrp0094fc7.3 | Fetal Endocrinology and Multisystem Disorders | ESPE2021

European Training Requirements for Competency in Paediatric Endocrinology and Diabetes 2021

Busiah Kanetee , Peet Aleksandr , Tornese Gianluca , Weintrob Naomi , Patel Leena , Hamza Rasha ,

Background: A Europe-wide training program in Paediatric Endocrinology and Diabetes (PED) was initiated by Professor Leo Van den Brande in 1976. PED was recognised as a subspecialty in 1996 by the European Board of Paediatrics (EBP), which is a section of the Union of European Medical Specialists (UEMS). UEMS aims to ensure high standards for training across Europe and the minimum requirements are set out in the European Training Requirements (ETR). The first ...

hrp0092p1-6 | Adrenals and HPA Axis | ESPE2019

Health status of children with Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency in the United Kingdom: results of a multi-centre cohort study

Bacila Irina-Alexandra , Mahdi Sundus , Acerini Carlo L , Krone Ruth , Patel Leena , Alvi Sabah , Randell Tabitha , Gevers Evelien , Dattani Mehul , Cheetham Timothy , Kyriako Andreas , Ryan Fiona , Crowne Elizabeth , Davies Justin H , Ahmed S. Faisal , Krone Nils P

Introduction: Congenital adrenal hyperplasia (CAH) is associated with long-term health problems. However, little is known about co-morbidities and their onset in children and young persons (CYP).Objective: To establish the health status of CYP with CAH across the United Kingdom.Methods: A multi-centre prospective study recruited 102 patients with 21-hydroxylase deficiency targeting...

hrp0082p2-d3-483 | Hypoglycaemia | ESPE2014

Neurodevelopmental Outcomes in Early and Late Presenting Congenital Hyperinsulinism

Mohamed Zainaba , Nicholson Jacqueline , Zamir Imran , Butler Thomas , Rigby Lindsey , Bowden Louise , Murray Philip , Steele Caroline , Rao Padidela Raja Narender , Patel Leena , Cosgrove Karen , Clayton Peter , Dunne Mark , Banerjee Indraneel

Background: Hypoglycaemia due to congenital hyperinsulinism (CHI) usually presents early (E-CHI) in the neonatal period, but late presentation (age >1 month) (L-CHI) also occurs. Adverse neurodevelopment is well recognised in both early and late CHI, but differences between both groups are not known.Objective and hypotheses: We examined a cohort of children with E-CHI and L-CHI to test neurodevelopmental outcomes in mid-childhood.<p class="abstex...

hrp0094fc1.3 | Adrenal | ESPE2021

Re-appraising the use of urinary steroid profiles for assessing therapy control in children with 21-hydroxylase deficiency – results from the CAH-UK cohort study

Bacila Irina , Lawrence Neil , Alvi Sabah , Cheetham Timothy , Crowne Elizabeth , Das Urmi , Dattani Mehul , Davies Justin H. , Gevers Evelien , Krone Ruth , Kyriakou Andreas , Patel Leena , Randell Tabitha , Ryan Fiona , Ahmed Faisal S. , Keevil Brian , Taylor Norman , Krone Nils ,

Introduction: Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) have specific plasma and urinary steroid patterns, with 11-oxygenatedC19 steroids established as key adrenal-specific androgens. Monitoring glucocorticoid (GC) replacement remains a challenge in the absence of reliable biomarkers.Aim: To reassess the urinary steroid profile of children with CAH in relation to plasma ...

hrp0092rfc13.2 | Adrenals and HP Axis | ESPE2019

Development of Novel Non-Invasive Strategies for Monitoring of Treatment Control in Patients with Congenital Adrenal Hyperplasia

Bacila Irina-Alexandra , Adaway Jo , Hawley James , Mahdi Sundus , Acerini Carlo L , Krone Ruth , Patel Leena , Alvi Sabah , Randell Tabitha , Gevers Evelien , Dattani Mehul , Cheetham Timothy , Kyriakou Andreas , Schiffer Lina , Ryan Fiona , Crowne Elizabeth , Davies Justin H , Ahmed S Faisal , Keevil Brian , Krone Nils P

Introduction: Glucocorticoid treatment remains a challenging aspect in the management of congenital adrenal hyperplasia (CAH). Current strategies for monitoring treatment are suboptimal and rely largely on frequent blood tests, which are traumatising in children and young persons (CYP). Recent evidence indicates a crucial role of 11-oxygenatedC19 androgens in the pathogenesis of CAH.Aim: To explore the use of 11-oxygenat...